Hypoxia-Induced Modulation of Bone Metabolism

Bone tissue resides in a naturally low‐oxygen niche, where cellular adaptation to hypoxia orchestrates the balance between formation and resorption. Central to this adaptation are hypoxia‐inducible factors (HIFs), transcriptional regulators that respond to oxygen tension by modulating genes involved in osteoblast and osteoclast differentiation, angiogenesis and matrix remodelling. In osteoblasts, HIF‐1α and HIF‐2α fine-tune the expression of key factors such as RANKL and RUNX2 to calibrate bone formation, while in osteoclasts hypoxia signalling alters resorptive capacity without markedly changing precursor fusion. Osteocytes sense oxygen fluctuations via prolyl hydroxylase domain proteins and relay signals through the WNT antagonist sclerostin to coordinate local bone mass. Collectively, these pathways underpin skeletal adaptation in development, ageing, metabolic disease and repair, and offer targets for therapeutic modulation of osteoporosis, diabetes-related bone loss and metastatic colonisation.

Research from Nature Portfolio

Recent studies have delineated distinct yet cooperative roles of HIF-1α and HIF-2α in bone remodelling. HIF-1α overexpression in osteoblasts was shown to inhibit RUNX2-driven differentiation via induction of Twist2, while unexpectedly upregulating RANKL through a HIF-2α-dependent mechanism. This interplay was validated in conditional knockout and osteoporosis models, revealing that HIF-1α governs bone formation and, indirectly via HIF-2α, osteoclast activation. In a complementary investigation, selective deletion of prolyl hydroxylase domain protein-2 in osteocytes elicited a high-bone-mass phenotype. Enhanced HIF-1α signalling promoted sirtuin-1-mediated deacetylation of the Sost promoter, suppressing sclerostin expression and potently stimulating WNT/β-catenin-driven bone formation, even under oestrogen deficiency or mechanical unloading.

Hypoxia-Induced Modulation of Bone Metabolism publication trend

The graph below shows the total number of articles in hypoxia-induced modulation of bone metabolism across all publications each year (not limited to Nature Index journals).

Technical terms

Hypoxia‐inducible factor (HIF): Transcription factor stabilised under low oxygen that regulates genes for angiogenesis and metabolism.

Osteoblast: Bone‐forming cell responsible for synthesis and mineralisation of bone matrix.

Osteoclast: Multinucleated cell that resorbs bone by secreting acids and proteases.

RANKL: Cytokine produced by osteoblasts and osteocytes that drives osteoclast differentiation and activation.

Sclerostin (SOST): Osteocyte‐derived WNT antagonist that inhibits bone formation.

Prolyl hydroxylase domain (PHD): Oxygen‐sensing enzyme that targets HIF for degradation under normoxia.

References

1. Activation of the osteoblastic HIF-1α pathway partially alleviates the symptoms of STZ-induced type 1 diabetes mellitus via RegIIIγ. Experimental & Molecular Medicine (2024).
2. Use of oxygen-loaded nanobubbles to improve tissue oxygenation: Bone-relevant mechanisms of action and effects on osteoclast differentiation. Biomaterials (2023).
3. Differential but complementary roles of HIF-1α and HIF-2α in the regulation of bone homeostasis. Communications Biology (2024).
4. Eight Weeks of Intermittent Exercise in Hypoxia, with or without a Low-Carbohydrate Diet, Improves Bone Mass and Functional and Physiological Capacity in Older Adults with Type 2 Diabetes. Nutrients (2024).
5. Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin. Nature Communications (2018).
6. Hypoxia‐inducible factor 1‐alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl‐4‐hydroxylase 2. The Journal of Pathology (2017).